{"id":8901,"date":"2020-04-10T14:48:54","date_gmt":"2020-04-10T09:18:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8901"},"modified":"2024-09-18T13:17:13","modified_gmt":"2024-09-18T07:47:13","slug":"car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","title":{"rendered":"Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL)"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a040ca3e50b3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a040ca3e50b3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\/#Acute_lymphocytic_leukemia_epidemiology\" >Acute lymphocytic leukemia\nepidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\/#ALL_treatment_approaches_and_unmet_needs\" >ALL treatment approaches and unmet needs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\/#CAR_%E2%80%93_T_cell_therapy_market_in_Acute_lymphocytic_leukemia\" >CAR &#8211; T cell therapy market in  Acute lymphocytic leukemia<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\/#CAR-T_cell_therapy_market_in_ALL_Pipeline\" >CAR-T cell therapy market in  ALL: Pipeline<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\/#Way_ahead\" >Way ahead<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p class=\"has-text-align-center has-cyan-bluish-gray-background-color has-background\"> <em>DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to <strong>USD 1,315.7 million<\/strong> in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. <\/em> <\/p>\n\n\n\n<p>Acute lymphocytic leukemia (ALL) is a tumor that afflicts bone marrow and hampers the production of healthy White blood cells. ALL is acute cancer denoting its rapid progression, if not treated can be fatal within a few months. One of the most common types of cancer, Acute lymphocytic leukemia starts from the bone marrow and invades the other parts of the body through lymph nodes, spinal cord, liver, spleen, and central nervous system.<\/p>\n\n\n\n<p>As the name suggests, ALL\nresults in soaring in production of lymphocytes, and on the basis of types on\nthe type of lymphocytes affected, ALL is categorized into <strong>B-cell ALL<\/strong>, <strong>T-cell\nALL<\/strong>, <strong>Burkitt-type ALL<\/strong> and <strong>Philadelphia chromosome<\/strong>&#8211;<strong>positive\nALL (Ph+ ALL)<\/strong>. <\/p>\n\n\n\n<p>Some patients have also\nreported a type of leukemia called <strong>biphenotypic acute leukemia<\/strong>, or mixed\nphenotype acute leukemia or ambiguous lineage acute leukemia, i.e., a\nleukaemia, which has characteristics of both ALL and\/or acute myeloid leukemia\n(AML).<\/p>\n\n\n\n<p>Acute lymphoblastic\nleukemia occurs due to mutations in the DNA of the bone marrow directing it to\ncontinue its proliferation non-stop. This results in a quickened production of lymphoblasts\nthat fail to mature into lymphocytes. Although, the etiology of acute\nlymphoblastic leukemia remains unknown; however, certain environmental factors\nhave been implicated in the etiology of Acute Lymphocytic Leukemia such as\nexposure to benzene, ionizing radiation, or previous exposure to chemotherapy\nor radiotherapy, as per <em>Yana Puckett<\/em>, et al. <\/p>\n\n\n\n<p>Also known as acute\nlymphoblastic leukemia, signs and symptoms of the disease include gum bleeding,\npain in the bones, fever, nose-bleeds, swollen lymph nodes, shortness of\nbreath, fatigue, and others. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acute_lymphocytic_leukemia_epidemiology\"><\/span><strong>Acute lymphocytic leukemia\nepidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Acute lymphoblastic\nleukemia is the second most common acute leukaemia, with 80% of the all cases are\ndiagnosed in children. ALL is pretty much less common in adults; however,\nsurvival rates and long-term prognosis for adults depict a grim picture.&nbsp; According to the American cancer society,\nAcute lymphocytic leukaemia incidence is estimated to be at 1.6 per 100\u2009000 population.\nMoreover, the year 2016 witnessed approximately newly ALL diagnosed 6590 out of\nwhich, 1400 resulted in deaths.<\/p>\n\n\n\n<p>According to Paul, S et\nal., Acute lymphoblastic leukaemia incidence follows a bimodal distribution,\ni.e., the cases are either diagnosed during childhood or around the age of\n50.&nbsp; <\/p>\n\n\n\n<p>DelveInsight estimates\nthat by 2020, Acute lymphoblastic leukaemia incidence would range between 0.4\nto 2 per 100,000 population in the Asia-Pacific and South American countries.\nMoreover, globally, the prevalence is expected to increase during the forecast\nperiod (2017-2030). <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ALL_treatment_approaches_and_unmet_needs\"><\/span><strong>ALL treatment approaches and unmet needs <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The clinical hallmark of\nALL is altered genome and chromosomal abnormalities in differentiation and\nproliferation of lymphoid precursor cells of B-cell lineage and T-cell lineage.\nIdentification of genetic alterations paves the way for better management of\nthe disease and better prognosis as compared to traditional methods based on\nage, WBC count, and others. <\/p>\n\n\n\n<p>Despite major breakthroughs in identifying alteration and defining prognosis of ALL, the backbone of the treatment stays multi-agent chemotherapy comprising three phases, namely, remission, consolidation, and maintenance, with CNS prophylaxis at intervals throughout therapy. The remission therapy includes the use of vincristine, corticosteroids and anthracycline with allogeneic stem cell transplantation for eligible candidates. As per the American Cancer Association, chemotherapy is the mainstay of ALL treatment. <strong>Amsacrine<\/strong> (NordMedica), <strong>cyclophosphamide<\/strong> (Baxter), and <strong>cytarabine<\/strong> (Pfizer) are some of the cytotoxic drugs available for chemotherapy in ALL used for the destruction of cancer cells. Therefore, the rising importance of chemotherapy is a major contributing factor behind the growth of <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphoblastic-leukemia-all-market\">Acute lymphoblastic lymphoma market size<\/a>. <\/p>\n\n\n\n<p>Dose intensification has brought improved outcomes in paediatric patients; however, the limitation in the use of theses drugs are elderly patients are unable to tolerate such high doses regimens and carry a particularly poor prognosis as only 30\u201340% of adult ALL patients manages to achieve long-term remission. Moreover, many times chemotherapy do not reach the marrow or drugs do not act in a certain manner required to get rid of tumor cells. Associated side effects such as hair loss, diarrhoea, haemorrhage have always been a cause of concern. <\/p>\n\n\n\n<p>It is therefore paramount to focus shift from conventional chemotherapy\nmethods to a treatment approach that brings relief from the side effects and\nare efficient in patients of all age-groups. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR_%E2%80%93_T_cell_therapy_market_in_Acute_lymphocytic_leukemia\"><\/span><strong>CAR &#8211; T<\/strong> cell therapy market in  <strong>Acute lymphocytic leukemia<\/strong>  <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/13084334\/info-2-1024x536.jpg\" alt=\"CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia \" class=\"wp-image-8914\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/13084334\/info-2-1024x536.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/13084334\/info-2-300x157.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/13084334\/info-2-768x402.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/13084334\/info-2.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption> <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia <\/a><\/strong> <\/figcaption><\/figure>\n\n\n\n<p>Chimeric antigen receptor\n(CAR) T-cell therapy has successfully cured cancers wherever chemotherapy failed.\nThe treatment involves correction of genetic errors in autologous T-cells\ndirecting it to express a tumor antigen \u2013 CAR \u2013 chimeric antigen receptor &#8211; followed\nby ex vivo cell expansion and re-infusion back to the patient. <\/p>\n\n\n\n<p>Recently CAR-T cell therapies have emerged significantly to target antigens in Acute lymphoblastic leukaemia patients. Results of several clinical trials testing the efficacy and safety of CAR-T cell immunotherapy have shown some promising results. The year 2017 marked a milestone after the FDA approved tisagenlecleucel (CTL019) &#8211; under the brand name <strong>Kymriah<\/strong> &#8211; by <strong>Novartis<\/strong>, a CD19-directed CAR-T cell product for the treatment of relapsed\/refractory ALL. It is the only approved cell therapy available in the Acute lymphoblastic leukaemia market for paediatric patients. <\/p>\n\n\n\n<p>The approval of Kymriah\nresulted in an influx of the investors investing in several pharma and biotech companies\ndeveloping their immunotherapy pipeline candidates to remain afloat in the\nhighly competitive environment.<\/p>\n\n\n\n<p>Despite these, the strict\nregulatory approvals with a less favourable outcome for the therapeutics and\nthe adverse side effects of the drugs used in the therapy hinder the growth of the\nmarket worldwide.<\/p>\n\n\n\n<p>The global Acute Lymphoblastic\nLeukaemia market boasts of a robust clinical pipeline under development in\nvarious stages of development. The emergence of potential therapies, <strong>MB-CART19.1<\/strong>\n(Miltenyi), <strong>PBCAR0191<\/strong> (Precision BioSciences), <strong>AUTO3<\/strong> (Autolus\nLimited) will significantly impact the market in the future.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_cell_therapy_market_in_ALL_Pipeline\"><\/span>CAR-T cell therapy market in  ALL<strong>: Pipeline <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Acute Lymphoblastic Leukemia market consists of the big pharma players as well as the mid-sized companies, hence is moderately competitive. Moreover, <em>DelveInsight estimates by 2030, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">Car-T cell therapy market in Acute lymphoblastic leukaemia<\/a> would approximate to <strong>USD 1,315.7 million<\/strong> in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. <\/em><\/p>\n\n\n\n<p><strong>MB-CART19.1<\/strong>\n&#8211; a CAR T-cell therapy by <strong>Miltenyi Biotec<\/strong> is in Phase I\/II clinical\ntrial for the treatment of r\/r B-cell lymphoma, and acute and chronic lymphocytic\nleukemia. The drug is currently in phase I\/II stage for the treatment of Non-Hodgkin&#8217;s\nlymphoma, and in phase I stage of the clinical trial for the treatment of\npatients with r\/r CD19-positive B cell malignancies. <\/p>\n\n\n\n<p><strong>PBCAR0191<\/strong>\n&#8211; novel CD19 targeted allogeneic CAR T therapy candidate under development by <strong>Precision\nBioSciences<\/strong> for the treatment of relapsed\/refractory (r\/r) B-cell acute\nlymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL), is currently in\nphase I\/IIa clinical trial. The FDA has granted PBCAR0191 Orphan Drug Designation\nfor the treatment of ALL.<\/p>\n\n\n\n<p><strong>AUTO3<\/strong>\n\u2013 a CAR T-cell therapy for T-cell Lymphomas is under development by <strong>Autolus\nLimited<\/strong>. The therapeutic candidate is in phase I\/II of development for the treatment\nof T-cell lymphomas. In April 2019, the FDA granted orphan drug designation to\nAUTO3. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_ahead\"><\/span><strong>Way ahead <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>As per DelveInsight analysts, the advances made in CAR-T cell therapy since the introduction of the idea of developing CAR-T cells to tackle malignancies until the timeline reaching the present date have been commendable. The decades-long journey and the approval of therapies and many others receiving designations heralds to the bright future of CAR-T cell therapy market in  Acute lymphocytic leukemia. <\/p>\n\n\n\n<p>Moreover, ongoing research\nshows that the day is not far enough when CAR-T cell therapy would be the talk\nof the town grabbing a maximum chunk of the market, providing relief to\npatients who have acute lymphoblastic leukaemia. <\/p>\n\n\n\n<p>In addition to incremental R&amp;D, rising focus of most of the pharmaceutical companies in <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology\/\">oncology<\/a>, it is expected that few new small-sized companies will also penetrate the market shortly. The recent advances in survival rates and positive clinical outcomes in patients with B cell malignancies also highlight the future scope of CAR -T cell therapy market. However; the b<a href=\"https:\/\/www.delveinsight.com\/blog\/the-era-of-gene-therapy-and-the-billion-dollar-tag\/\">illion-dollar price for one-time therapy<\/a> is something which till date remains debatable. <\/p>\n\n\n\n<p>Conclusively, DelveInsight estimates an increase in the size of CAR T-Cell Therapy market for Acute Lymphoblastic Leukemia anticipated for the study period, 2017\u20132030 attributed to increasing incident population of Acute Lymphoblastic Leukemia patients in the 6MM, along with the expected entry of premium price asset such as antigens, cell therapies will have an impact on market size. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflicts bone marrow and hampers the production of healthy White [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8904,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[17564,12078,12079,12081,18229,18222,18224,12288,1693,18228,423,18227,18223],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-8901","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-acute-lymphoblastic-leukemia","tag-acute-lymphocytic-leukemia","tag-all","tag-all-market","tag-autolus-limited","tag-b-cell-all","tag-burkitt-type-all","tag-car-t-cell-therapy-market","tag-kymriah","tag-miltenyi-biotec","tag-novartis","tag-precision-biosciences","tag-t-cell-all","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CAR-T cell therapy market in ALL | Acute lymphocytic leukemia<\/title>\n<meta name=\"description\" content=\"CAR-T cell therapy market in Acute lymphocytic leukemia would be USD 1,315.7 million in the 6MM by 2030 attributed to increasing ALL incidence...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T cell therapy market in ALL | Acute lymphocytic leukemia\" \/>\n<meta property=\"og:description\" content=\"CAR-T cell therapy market in Acute lymphocytic leukemia would be USD 1,315.7 million in the 6MM by 2030 attributed to increasing ALL incidence...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-10T09:18:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:47:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR-T cell therapy market in ALL | Acute lymphocytic leukemia","description":"CAR-T cell therapy market in Acute lymphocytic leukemia would be USD 1,315.7 million in the 6MM by 2030 attributed to increasing ALL incidence...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","og_locale":"en_US","og_type":"article","og_title":"CAR-T cell therapy market in ALL | Acute lymphocytic leukemia","og_description":"CAR-T cell therapy market in Acute lymphocytic leukemia would be USD 1,315.7 million in the 6MM by 2030 attributed to increasing ALL incidence...","og_url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-10T09:18:54+00:00","article_modified_time":"2024-09-18T07:47:13+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia","name":"CAR-T cell therapy market in ALL | Acute lymphocytic leukemia","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1.jpg","datePublished":"2020-04-10T09:18:54+00:00","dateModified":"2024-09-18T07:47:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"CAR-T cell therapy market in Acute lymphocytic leukemia would be USD 1,315.7 million in the 6MM by 2030 attributed to increasing ALL incidence...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-in-acute-lymphocytic-leukemia#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1.jpg","width":772,"height":482,"caption":"CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/10144007\/ALL1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">ALL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">ALL Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Autolus Limited<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">B Cell ALL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Burkitt Type ALL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Kymriah<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Miltenyi Biotec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Precision Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">T Cell ALL<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/span>","<span class=\"advgb-post-tax-term\">ALL<\/span>","<span class=\"advgb-post-tax-term\">ALL Market<\/span>","<span class=\"advgb-post-tax-term\">Autolus Limited<\/span>","<span class=\"advgb-post-tax-term\">B Cell ALL<\/span>","<span class=\"advgb-post-tax-term\">Burkitt Type ALL<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/span>","<span class=\"advgb-post-tax-term\">Kymriah<\/span>","<span class=\"advgb-post-tax-term\">Miltenyi Biotec<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Precision Biosciences<\/span>","<span class=\"advgb-post-tax-term\">T Cell ALL<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 10, 2020","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Apr 10, 2020 2:48 pm","modified":"Updated on Sep 18, 2024 1:17 pm"},"featured_img_caption":"CAR-T Cell Therapy Market In ALL- Acute lymphocytic leukemia ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8901"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8901\/revisions"}],"predecessor-version":[{"id":29591,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8901\/revisions\/29591"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8904"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8901"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8901"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}